Subramanian says report will serve as strategic roadmap for industry
The globally recognized Indian pharmaceutical industry has set a bold target of reaching US$450 billion by 2047, according to a report ‘Reimagining Pharma and Healthcare for India@100’.
The report meticulously explores the industry’s potential to become an integral part of the global pharma supply chain, foster innovation, and ensuring sustainable and equitable healthcare access for all.
“The insights presented in the report will serve as a strategic roadmap for industry leaders, policymakers, and stakeholders alike,” Suresh Subramanian, Partner and National Lifesciences Leader, EY Parthenon, said.
The Organisation of Pharmaceutical Producers of India (OPPI) released the report at its flagship Annual Summit on the 23 Nov 2023 in New Delhi.
The report, a collaboration between OPPI and EY Parthenon, outlines an ambitious trajectory for the pharmaceutical and healthcare sector. fiinews.com
